Jiangsu Kanion Pharmaceutical Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd., known as Kanion or 康缘药业, is a Chinese pharmaceutical company whose stated core business is the research, manufacture, and sale of modern traditional Chinese medicines. Its official website presents the company as a large Chinese medicine industrial enterprise and describes its mission as “revitalizing Chinese medicine and serving the country.” The company’s stated vision is “quality Chinese medicines, Kanion intelligent manufacturing.” Kanion organizes its product portfolio into classical formula, cardiovascular and cerebrovascular, gynecology, orthopedics, anti-infective, and other categories. Its official product-center page describes the approach as innovating and developing modern medicines in accordance with traditional Chinese medicine theory. Company materials also describe a broader development model built around traditional Chinese medicines, chemical medicines, and biological medicines. The supplied sources do not provide a complete product catalogue or identify all individual product brands. A company news item identifies Jinzhen Oral Liquid as a core pediatric proprietary Chinese medicine. Research and manufacturing are prominent parts of Kanion’s corporate positioning. The company reports approval of 61 new Chinese medicines, more than 700 authorized invention patents, and participation in more than 40 science and technology projects. It also describes national-level research and engineering platforms focused on process control and intelligent manufacturing for Chinese medicines. These figures and descriptions are statements from the company’s official materials. Kanion identifies itself as a domestic A-share listed company and gives its Shanghai Stock Exchange code as 600557.SH. The supplied official pages do not specify its founder, founding year, ultimate owner, or detailed headquarters address. The company website is based in Jiangsu, China, and presents the enterprise as active in product development, manufacturing, industry engagement, and social responsibility. Its reported activities include public-welfare work, disaster relief, poverty alleviation, and environmental initiatives.

Kanion’s official website describes the company as having developed over a fifty-year period, but the supplied material does not establish a precise founding year or name a founder. Its account centers on the development of an enterprise that researches, manufactures, and sells Chinese medicines. The company presents “revitalizing Chinese medicine and serving the country” as its mission, and “quality Chinese medicines, Kanion intelligent manufacturing” as its vision. The company describes its development in phases—before 2000, 2000–2004, 2005–2009, 2010–2014, 2015–2019, and 2020 onward—but the supplied page does not detail individual events within those periods. Accordingly, the available evidence supports a broad account of long-term development, rather than a precise chronology of early corporate milestones. In its current self-description, Kanion says it has grown into a listed enterprise combining research, production, and sales of Chinese medicines. It reports approval of 61 new Chinese medicines, authorization of more than 700 invention patents, and participation in more than 40 national science and technology projects. It also says it has received national-level recognition for high-technology enterprise status, technological innovation, and intellectual property, and describes research platforms for Chinese medicine process control and intelligent manufacturing. These are company-reported figures and credentials. Kanion presents its later development strategy as a cluster innovation model built around traditional Chinese medicines, chemical medicines, and biological medicines. Its product portfolio is organized into classical formula, cardiovascular and cerebrovascular, gynecology, orthopedics, anti-infective, and other categories. The company’s website identifies its listed status and stock code as 600557.SH. The sources supplied here do not identify the company’s founder, exact founding date, ownership structure, or detailed headquarters address. The company also describes social responsibility as part of its corporate record, citing participation in charitable activities, disaster relief, targeted poverty alleviation, and environmental protection. Recent items on its news page report participation in healthcare-industry events, the release of an information-security practice white paper, product recognition, and inclusion of exclusive products in a national medicines list. The dated entries are company news reports and are presented here as such, not as independently verified assessments.

• Seven exclusive products reported included in the 2026 National Essential Medicines List

• Jinzhen Oral Liquid reported to receive a 2026 Xipu Gold Award

• First company information-security practice white paper released

A research- and manufacturing-led Chinese pharmaceutical company centered on modern traditional Chinese medicines, with stated innovation activity spanning traditional Chinese medicines, chemical medicines, and biological medicines.

• Jinzhen Oral Liquid

  Identified in company news as a core pediatric proprietary Chinese medicine; the company reported that it received a 2026 Xipu Gold Award.

• Classical formula product range

  A product category listed by the official product center.

• Cardiovascular and cerebrovascular product range

  A product category listed by the official product center.

• Gynecology product range

  A product category listed by the official product center.

• Orthopedics product range

  A product category listed by the official product center.

• Anti-infective product range

  A product category listed by the official product center.

• 2023

  R&D expense recognition violation: annual report overstated by 10.5 million yuan, company warned

  In May 2023, the Jiangsu Securities Regulatory Bureau determined that Kanion Pharmaceutical's recognition of R&D expenses in 2019 did not comply with accounting standards and overstated expenses by 10.5 million yuan, issuing warning letters to the company and its then chief financial officer and board secretary.

  Source

Read more

• Adopts a three-part cluster innovation modelOther

• Positions intelligent manufacturing and research as strategic prioritiesOther

1. 1江苏康缘药业股份有限公司_品牌官网-康缘药业kanion.com
2. 2产品中心-康缘药业kanion.com
3. 3走进康缘-康缘药业kanion.com
4. 4公司新闻-康缘药业kanion.com
5. 5R&D expense recognition violation: annual report overstated by 10.5 million yuan, company warnedjiemian.com